Floatz logo

Polyiclc

Metastatic Colon Cancer

Asha NayakPhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Metastatic Colon Cancer cohort.

Asset / SponsorPhaseRating
Fruquintinib
Peking University
Phase 3BBB
Adebrelimab
Sapience Therapeutics
Phase 3BB
Cetuximab
Shanghai 6th People's Hospital
Phase 3BB
PANITUMUMAB
University of Campania Luigi Vanvitelli
Phase 2BB
Nivolumab
Massachusetts General Hospital
Phase 3B

View all 28 →

Same molecule, other indications

Polyiclc is also rated in:

Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
B
Indicative ·
63 / 100
View asset →
melanomaDormant
B
Indicative ·
63 / 100
View asset →
ocular melanomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →